StandardX Ltd

Based in the UK, StandardX Ltd, operates as a producer of medical, industrial, and fusion-related isotopes using particle accelerator technology. Based in London, the UK and founded in 2025, StandardX Ltd produces isotopes utilizing advanced particle accelerator technology. In September 2026, StandardX Ltd raised GBP 10 mn in Seed funding by Brevan Howard, East X Ventures, and other investors. The funding will support the development of its accelerator-based isotope refinery and initial production of medical isotopes.

StandardX specializes in the production of isotopes, focusing on developing the world's first scalable isotope production platform utilizing a compact particle accelerator. The company offers a versatile portfolio of isotopes aimed at addressing critical challenges in medicine, industry, and energy. Their medical isotopes are essential for diagnostic and therapeutic applications, playing a pivotal role in cancer treatment through targeted therapies that rely on precise isotopic compositions. In the industrial sector, StandardX's isotopes enhance the performance and resilience of modern systems, while in the energy domain, they produce tritium, a crucial isotope for advancing fusion energy technology.

StandardX caters to a diverse client base, including healthcare providers, industrial manufacturers, and energy companies across North America, Europe, and select markets in Asia. StandardX generates revenue through direct sales of its isotope products to various stakeholders in the healthcare, industrial, and energy sectors. Transactions typically involve long-term partnerships with healthcare institutions and industrial firms that require sustained access to diagnostic and therapeutic isotopes, as well as tritium for fusion applications. The company's revenue model encompasses direct sales agreements and collaborations that may include subscription-based elements for ongoing supply commitments.

Pricing structures are tailored to the specific isotope products and frequency of delivery, with clients engaging in contractual agreements that outline cost per unit for medical, industrial, and energy-related isotopes. In September 2026, StandardX Ltd raised GBP 10 mn in Seed funding to develop its accelerator-based isotope refinery, support initial production of medical isotopes, and expand isotope supply for cancer treatment, medical research, and fusion energy applications.